RAGE-Fc
COVID-19 (Lung Inflammation/Cytokine Storm)
Key Facts
About Galactica Pharmaceuticals
Galactica Pharmaceuticals is a private, preclinical biotech founded in 2020 (with roots dating to 2005) and based in Boston, USA. Its core asset is a proprietary RAGE-Fc fusion protein, which has shown promising preclinical efficacy in COVID-19, diabetic complications, and macular degeneration, positioning it as a potential multi-indication therapeutic. The company is 'IND-ready' and plans to file its first IND within 15-18 months, with a potential accelerated path for COVID-19, while operating under a capital-efficient virtual model.
View full company profileAbout Galactica Pharmaceuticals
Galactica Pharmaceuticals is a private, preclinical biotech founded in 2020 (with roots dating to 2005) and based in Boston, USA. Its core asset is a proprietary RAGE-Fc fusion protein, which has shown promising preclinical efficacy in COVID-19, diabetic complications, and macular degeneration, positioning it as a potential multi-indication therapeutic. The company is 'IND-ready' and plans to file its first IND within 15-18 months, with a potential accelerated path for COVID-19, while operating under a capital-efficient virtual model.
View full company profileAbout Galactica Pharmaceuticals
Galactica Pharmaceuticals is a private, preclinical biotech founded in 2020 (with roots dating to 2005) and based in Boston, USA. Its core asset is a proprietary RAGE-Fc fusion protein, which has shown promising preclinical efficacy in COVID-19, diabetic complications, and macular degeneration, positioning it as a potential multi-indication therapeutic. The company is 'IND-ready' and plans to file its first IND within 15-18 months, with a potential accelerated path for COVID-19, while operating under a capital-efficient virtual model.
View full company profile